This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Ranibizumab for the treatment of age-related macular degeneration

Ranibizumab for the treatment of age-related macular degeneration
Reviewed by Nana Theodorou

1 April 2015 | Nana Theodorou | EYE - Vitreo-Retinal

This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12 months or monthly for four months followed by repeat ranibizumab injections (RI) on a pro-re nata basis. Thirty patients participated with 36 eligible eyes. Outcome measures were best corrected standardised visual acuities, central 1mm thickness, subretinal fluid and cystoid macular oedema. Both groups showed reductions of the central 1mm thickness with vision improvement seen earlier for those receiving the higher dose. Cataract progression was similar in both groups but RPE tears developed most often in the 2.0mg dose. The authors conclude that although the visual and anatomical outcomes (weeks four and eight) were similar at the end of the study, the higher dose showed more rapid reductions and complete resolution of pigment epithelial detachment (PED). 

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.
Chan C, Abraham P, Sarraf D, et al.
EYE
2015:29:80-7.
Share This
CONTRIBUTOR
Nana Theodorou

BMedSCi (Hons) PhD, Sheffield Teaching Hospitals NHS Foundation Trust, Clinical Research Office, 11 Broomfield Road, Sheffield, S10 2SE, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency